back to top
Wednesday, 9 October, 2024
HomeMedicinePrice of lifesaving drug deliberately hiked – UK court

Price of lifesaving drug deliberately hiked – UK court

British taxpayers were forced to pay millions of pounds for a lifesaving drug after a pharmaceutical company deliberately inflated the cost, pushing it up by a whopping 10 000%, a court has ruled.

Auden Mckenzie and Actavis UK, now known as Accord-UK, engaged in “cartel behaviour” by paying off competitors and raising the price of hydrocortisone tablets by an astronomical amount between 2008 and 2018.

NHS spending on the treatment then rose from around £500 000 a year to more than £80m due to the company’s monopoly, the Court of Appeal heard.

The Independent reports that the drug is used by tens of thousands of people in the UK to treat, in some cases, life-threatening conditions like Addison’s disease.

In 2021, the Competition and Markets Authority (CMA) found that the company had charged excessive and unfair prices for the hydrocortisone tablets.

But the Competition Appeal Tribunal (CAT) overturned the decision earlier this year – meaning the £106m fines the company faced were thrown out.

Now, the Court of Final Appeal has upheld the CMA’s original decision.

Sarah Cardell, chief executive of the CMA, said: “When the CAT decided the CMA’s decision should be set aside despite being correct on the merits, we remained determined to see the case through and took the fastest route to correct this.

“We’re delighted that the Court of Appeal recognised that the CMA’s case was consistent, clear and fairly defended on appeal.”

Between 2011 and 2015, Auden, which merged with Actavis in 2015, agreed to make substantial monthly payments to pharmaceutical company Wayside in exchange for that company agreeing not to market its own version of the drug, the CMA found.

It also found that Auden Mckenzie and Actavis UK agreed to make substantial monthly payments to drug company AMCo in exchange for it agreeing not to go to market independently with its own tablets between 2012 and 2016.

Previously, the CMA described the company’s arrangements as “flagrantly anti-competitive” and “cartel behaviour”.

Hydrocortisone, a steroid medicine, works by calming down the body’s immune response to reduce pain, itching and swelling, and can also be used as hormone replacement for people who do not have enough of the natural stress hormone cortisol.

 

The Independent article – British company deliberately hiked price of lifesaving drug, court rules (Open access)

 

See more from MedicalBrief archives:

 

Pharmas named in major generic drug price-fixing suit

 

Aspen’s 1,800% price-hike collusion windfall from NHS

 

Anti-competitive acts in UK to cost SA’s Aspen almost R190m

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.